uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
42.76
-2.52 (-5.57%)
At close: Sep 23, 2026, 4:00 PM EDT
42.85
+0.09 (0.21%)
After-hours: Sep 23, 2026, 4:38 PM EDT
uniQure Employees
uniQure had 221 employees as of December 31, 2025. The number of employees increased by 12 or 5.74% compared to the previous year.
Employees
221
Change (1Y)
12
Growth (1Y)
5.74%
Revenue / Employee
$84,489
Profits / Employee
-$1,141,217
Market Cap
2.97B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 221 | 12 | 5.74% |
| Dec 31, 2024 | 209 | -271 | -56.46% |
| Dec 31, 2023 | 480 | -21 | -4.19% |
| Dec 31, 2022 | 501 | 38 | 8.21% |
| Dec 31, 2021 | 463 | 131 | 39.46% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Zai Lab | 1,784 |
| Arcus Biosciences | 601 |
| Denali Therapeutics | 507 |
| Arcutis Biotherapeutics | 354 |
| Dyne Therapeutics | 289 |
| Immunome | 247 |
| Celldex Therapeutics | 198 |
QURE News
- 21 days ago - uniQure seeks US approval for Huntington's gene therapy after FDA reversal - Reuters
- 21 days ago - uniQure submits biologics license application to FDA for ifezuntirgene inilparvo - TheFly
- 21 days ago - uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington's Disease - GlobeNewsWire
- 21 days ago - uniQure resumed with an Outperform at William Blair - TheFly
- 7 weeks ago - uniQure price target lowered to $60 from $65 at Barclays - TheFly
- 1 month ago - Wolfe upgrades uniQure to Outperform, sees ‘clear path to approval’ for AMT-130 - TheFly
- 1 month ago - uniQure upgraded to Outperform from Peer Perform at Wolfe Research - TheFly
- 1 month ago - uniQure Earnings Call Transcript: Q2 2026 - Transcripts